Newstral
Fresenius Kabi
- Denosumab Biosimilar Updates - June 2024jdsupra.com
- Amgen Files BPCIA Lawsuit Against Celltrion’s Proposed Prolia® / Xgeva® (Denosumab) Biosimilar CT-P41jdsupra.com
- Fresenius Kabi Announces FDA Acceptance of aBLA for Prolia® / Xgeva® (denosumab) Biosimilar Candidate FKS518jdsupra.com
- Biosimilar Launch and Approval Updates – Tyenne® (tocilizumab-aazg), Xlucane™ (ranibizumab), Hercessi™ (trastuzumab-strf)jdsupra.com
- Fresenius Kabi Announces Launch of TYENNE, a Tocilizumab Biosimilar Referencing ACTEMRAjdsupra.com
- Genentech and Dr. Reddy’s Settle BPCIA Rituximab Litigationjdsupra.com
- Genentech and Dr. Reddy’s Settle BPCIA Litigation Against Proposed Rituxan Biosimilar DRL_RIjdsupra.com
- Fresenius Kabi and Formycon Reach Settlement Agreement for Ustekinumab Biosimilar Candidate in Europe and Canadajdsupra.com
- Fresenius Kabi Announces FDA Approval of TYENNE, a Tocilizumab Biosimilar Referencing ACTEMRAjdsupra.com
- Fresenius Kabi’s Actemra® biosimilar Tyenne® (tocilizumab-aazg) Approved in the U.S.jdsupra.com
- Biocon Settles with Janssen, Securing U.S. Market Entry Date for Ustekinumab Biosimilarjdsupra.com
- Chugai, Genentech, and Hoffmann-La Roche Dismiss Appeals of Actemra® Patent IPR Final Written Decisionsjdsupra.com
- Biosimilar Regulatory Updates - February 2024jdsupra.com
- Celltrion Submits an aBLA for Actemra® (tocilizumab) Proposed Biosimilar CT-P47jdsupra.com
- Year in Review: Top Regulatory Developments of 2023jdsupra.com
- Ustekinumab Antitrust Litigationjdsupra.com
- Updates on Patent Challenges by Biosimilar Manufacturers at the PTABjdsupra.com
- Janssen and Samsung Bioepis Settle STELARA (Ustekinumab) Litigationjdsupra.com
- New BPCIA Case Filed: Genentech and Biogen Want to Stop Dr. Reddy’s Rituximab Biosimilar from Entering the U.S. Marketjdsupra.com
- Formycon Enjoined From Manufacturing FYB202 Biosimilar of STELARA in Germanyjdsupra.com
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.